Evidence map›Paper›PMID 25799070›Full record

ArticlePloS one2015

Genetic heterogeneity of induced pluripotent stem cells: results from 24 clones derived from a single C57BL/6 mouse.

Cheng Li, Jeffery M Klco, Nichole M Helton, Daniel R George, Jacqueline L Mudd, Christopher A Miller, Charles Lu, Robert Fulton, Michelle O'Laughlin, Catrina Fronick and 2 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  2. Article
  3. Article
  4. Article
  5. Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cheng LiSection of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Jeffery M KlcoDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Nichole M HeltonSection of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Daniel R GeorgeSection of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Jacqueline L MuddSection of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Christopher A MillerThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Charles LuThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Robert FultonThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Michelle O'LaughlinThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Catrina FronickThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Richard K WilsonThe Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Timothy J LeySection of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Specimen Acquistition and Expression ProfilingP01CA101937 · NCI · WASHINGTON UNIVERSITY · PI LEY, TIMOTHY J. · 2003 to 2023
$58.8M
Molecular Pathogenesis of Acute Myeloid LeukemiaR35CA197561 · NCI · WASHINGTON UNIVERSITY · PI Timothy J. Ley · 2015 to 2026
$11.0M
DNMT3A MUTATIONS IN ACUTE MYELOID LEUKEMIAR01CA162086 · NCI · WASHINGTON UNIVERSITY · PI LEY, TIMOTHY J. · 2011 to 2015
$1.8M
NOTCH SIGNALING IN MYELOID DEVELOPMENTK08HL116605 · NHLBI · WASHINGTON UNIVERSITY · PI KLCO, JEFFERY M · 2013 to 2017
$711k
NCI NIH HHS CA101937NCI NIH HHS CA162086NCI NIH HHS P01 CA101937NCI NIH HHS P30 CA091842NCI NIH HHS P30CA91842NCI NIH HHS R01 CA162086NCI NIH HHS R35 CA197561NHLBI NIH HHS HL116605NHLBI NIH HHS K08 HL116605
6 · The paper itself

Abstract

Induced pluripotent stem cells (iPSCs) have tremendous potential as a tool for disease modeling, drug testing, and other applications. Since the generation of iPSCs "captures" the genetic history of the individual cell that was reprogrammed, iPSC clones (even those derived from the same individual) would be expected to demonstrate genetic heterogeneity. To assess the degree of genetic heterogeneity, and to determine whether some cells are more genetically "fit" for reprogramming, we performed exome sequencing on 24 mouse iPSC clones derived from skin fibroblasts obtained from two different sites of the same 8-week-old C57BL/6J male mouse. While no differences in the coding regions were detected in the two parental fibroblast pools, each clone had a unique genetic signature with a wide range of heterogeneity observed among the individual clones: a total of 383 iPSC variants were validated for the 24 clones (mean 16.0/clone, range 0-45). Since these variants were all present in the vast majority of the cells in each clone (variant allele frequencies of 40-60% for heterozygous variants), they most likely preexisted in the individual cells that were reprogrammed, rather than being acquired during reprogramming or cell passaging. We then tested whether this genetic heterogeneity had functional consequences for hematopoietic development by generating hematopoietic progenitors in vitro and enumerating colony forming units (CFUs). While there was a range of hematopoietic potentials among the 24 clones, only one clone failed to differentiate into hematopoietic cells; however, it was able to form a teratoma, proving its pluripotent nature. Further, no specific association was found between the mutational spectrum and the hematopoietic potential of each iPSC clone. These data clearly highlight the genetic heterogeneity present within individual fibroblasts that is captured by iPSC generation, and suggest that most of the changes are random, and functionally benign.

Indexed as

Genetic HeterogeneityAnimalsCell DifferentiationClone CellsFibroblastsGene ExpressionGene Expression ProfilingHematopoiesisHigh-Throughput Nucleotide SequencingInduced Pluripotent Stem CellsMaleMiceMice, Inbred C57BL

Identifiers

PMID25799070
PMCPMC4370741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.